Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes

Next Previous
X
Search
Trial Profile

A Phase 2 Multi-center Open-label Basket Trial of Nab-sirolimus for Adult and Adolescent Patients With Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Aug 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sirolimus (Primary)
  • Indications Biliary cancer; Bladder cancer; Carcinoma; Colorectal cancer; Endometrial cancer; Gastric cancer; Liver cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Soft tissue sarcoma; Solid tumours
  • Focus Registrational; Therapeutic Use
  • Acronyms PRECISION-1
  • Sponsors Aadi Bioscience

    • Most Recent Events

    • 07 Aug 2024 According to an Aadi media release, company will provide the next interim update of two-thirds of fully enrolled any tumor type presenting with qualifying TSC1 or TSC2 inactivating alterations from this trial, later in the third quarter (Q3 2024). The trial is fully enrolled, and study completion is expected by year-end.
    • 08 May 2024 Status changed from recruiting to active, no longer recruiting, according to an Aadi Bioscience media release.
    • 17 Mar 2024 According to an Aadi media release, data from this trial will be presented during an oral plenary at the Society of Gynecologic Oncology (SGO) Annual Meeting in San Diego, CA on March 17, 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top